香港中文大学医学院24日举行记者会公布，经过一项全国性多中心研究证实，新生物标志物CD9蛋白可预测急性淋巴细胞白血病患者的复发风险。这项研究成果有望为临床医生提供更加精准的治疗方案，提高治疗效果。
据悉，该研究由中大医学院、香港科技大学、香港浸会大学等多家机构共同完成。研究团队通过对1000多名急性淋巴细胞白血病患者的数据分析发现，CD9蛋白水平与患者复发风险密切相关。其中，CD9蛋白水平较高的患者复发风险更高。
据介绍，CD9蛋白是一种特殊的蛋白质，通常存在于成熟的淋巴细胞表面。在急性淋巴细胞白血病患者中，CD9蛋白的水平通常会升高。因此，通过检测患者的CD9蛋白水平，可以预测其复发风险。
这项研究成果对于急性淋巴细胞白血病的治疗具有重要意义。目前，临床上常用的治疗方法是通过化疗、放疗等方式来控制病情，但这些方法并不能完全消除患者复发的风险。而通过检测CD9蛋白水平，可以提前预测患者的复发风险，从而为临床医生提供更加精准的治疗方案，提高治疗效果。
此外，该研究成果还为未来的研究提供了新的思路和方向。研究人员表示，他们将继续深入研究CD9蛋白与急性淋巴细胞白血病之间的关系，以期能够开发出更加有效的治疗方法。
英语如下：
Title: New Biomarker CD9 Protein Can Predict Recurrence Risk of Acute Lymphoblastic Leukemia
Keywords: Biomarker, Lymphoma, Recurrence risk
News Content: The Chinese University of Hong Kong School of Medicine held a press conference on the 24th to announce that after a national multi-center study, it was confirmed that the new biomarker CD9 protein can predict the recurrence risk of patients with acute lymphoblastic leukemia. This research achievement is expected to provide more accurate treatment options for clinicians and improve treatment effectiveness.
It is reported that the study was completed by several institutions, including the Chinese University of Hong Kong School of Medicine, Hong Kong University of Science and Technology, and Hong Kong Baptist University. The research team analyzed data from more than 1000 patients with acute lymphoblastic leukemia and found that the level of CD9 protein was closely related to their recurrence risk. Among them, patients with higher CD9 protein levels had a higher risk of recurrence.
According to reports, CD9 protein is a special protein that usually exists on the surface of mature lymphocytes. In patients with acute lymphoblastic leukemia, the level of CD9 protein is usually elevated. Therefore, by detecting the patient’s CD9 protein level, it is possible to predict their recurrence risk.
This research achievement is of great significance to the treatment of acute lymphoblastic leukemia. At present, the commonly used treatment method in clinical practice is to control the disease through chemotherapy, radiotherapy and other means, but these methods cannot completely eliminate the risk of recurrence for patients. By detecting the CD9 protein level, it is possible to predict the recurrence risk in advance and provide more accurate treatment options for clinicians, thereby improving treatment effectiveness.
In addition, this research achievement also provides new ideas and directions for future research. The researchers said that they will continue to study the relationship between CD9 protein and acute lymphoblastic leukemia in depth, with a view to developing more effective treatment methods.
【来源】http://www.chinanews.com/life/2024/01-24/10152297.shtml
Views: 1